Salud financiera de hoja de balance de Aldeyra Therapeutics
Salud financiera controles de criterios 5/6
Aldeyra Therapeutics tiene un patrimonio de los accionistas total de $119.8M y una deuda total de $15.1M, lo que sitúa su ratio deuda-patrimonio en 12.6%. Sus activos y pasivos totales son $148.3M y $28.5M respectivamente.
Información clave
13.4%
Ratio deuda-patrimonio
US$15.20m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$83.04m |
| Patrimonio | US$113.42m |
| Total pasivo | US$27.88m |
| Activos totales | US$141.30m |
Actualizaciones recientes sobre salud financiera
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Revisiting Aldeyra Therapeutics
Sep 29Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun 01Aldeyra Therapeutics EPS beats by $0.01
May 06Aldeyra's conjunctivitis treatment meets late-stage study main goals
Apr 27How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Feb 23Aldeyra announces reproxalap's late-stage dry eye disease trial design
Feb 04Aldeyra initiates stock offering
Jan 13Aldeyra rated buy at Citi on reproxalap trial results
Jan 08Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($147.8M) de ALDX superan a sus pasivos a corto plazo ($22.3M).
Pasivo a largo plazo: Los activos a corto plazo de ALDX ($147.8M) superan a sus pasivos a largo plazo ($6.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ALDX tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ALDX ha crecido de 0% a 12.6% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ALDX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ALDX dispone de suficiente cash runway para 2.8 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.3% cada año.